, an Early Responsive Gene to Epigallocatechin Gallate, Inhibits Migration and Promotes Apoptosis in Esophageal Cancer Cells.

Esophageal cancer is a lethal disease that frequently occurs in developing countries, the incidence of which could be declined by drinking EGCG-enriched drinks or food. , whose complex functions and regulations are not yet fully understood, are induced by multiple inflammatory molecules and anti-tumor agents. Here, we identify 2444 EGCG-regulated genes in esophageal cancer cells, including . EGCG treatment recruits NF-κB at the promoter and enhancers of and activates gene transcription, which is repressed by NF-κB knockdown or inhibition. Loss of leads to a faster migration rate and less expression of Caspase-3 in cancer cells. Our study demonstrates that is a new tumor-suppressor gene involved in cell movement and apoptosis and could be a therapeutic target for esophageal cancer.